Botanical Solution (BSI) – a multiple award-winning innovator of sustainable, highly consistent, and cost-effective Advanced Botanical Materials, announced recently that it has secured an additional $7 million investment. Following the announcement of a partnership with Croda to accelerate the production of green, high quality, and pharma spec QS-21 at kilogram scale under GMP standards, the company went further in demonstrating through internal programs and collaboration with big pharma companies that its product is biochemically comparable and as immunogenic as the traditional QS-21 – obtained from ancient soapbark trees that grow predominantly in Chile.
What the funding round will be used for: The new funding round enables BSI to develop a robust and truly sustainable supply chain for the gold standard vaccine adjuvant QS-21 and boosts the expansion plan for agriculture, which includes the rollout of BSI’s flagship product Quillibrium in Mexico, Brazil, the US and EU. And the successful partnership with Syngenta established in 2019 has produced over 50% YOY growth of effective growers’ adoption of the product in Chile and Peru, accumulating over 100,000 acres treated to date.
The funding round, led by Otter Capital, was joined by the Latin American investors Boldo SpA and Quebec LP controlled by the Casanueva and Saval family offices focused on high tech and pharma investments respectively, among other investors.
BSI is on track to start delivering GMP materials to be used in the development of human vaccines later in the year.
KEY QUOTE:
“BSI is fortunate to have a strong group of investors who are enthusiastic about our progress and vision to impact multiple industries through our breakthrough technology and truly sustainable products. BSI is in a privileged position to solve major issues affecting the supply chain, cost and sustainability of the vaccine adjuvant QS-21 and addressing major challenges associated with disease control in modern agriculture.”
— CEO Gaston Salinas
